The in vitro activity, the in vivo properties and the human pharmocokinetics of cefuroxime, the new semisynthetic parenteral cephalosporin, have been described by O'Callaghan et al. (1976) , Ryan et al. (1976) and Foord (1976) .
The present study was undertaken to determine the clinical and bacteriological efficacy, patient tolerance and toxicity of i.m. administration of cefuroxime in 40 patients with urinary tract infections.
Patients and Methods Forty out-and in-patients with urinary tract infection, as evidenced by counts of 105 bacteria/ ml of urine, were treated with cefuroxime (1500 mg/day) administered in 3 divided doses at 8 h intervals. The duration of therapy was 7-10 days, with an average of 8.0 days per patient. There were 24 males and 16 females. Their age range was 23-74 years with a mean of 51.7. Underlying urologic conditions were common, as indicated in Table 1. Laboratory controls were performed before, during, at the end of treatment and 6 weeks later.
The following tests were carried out: Routine urine analysis (albumin, glucose. pH and sediment). Urine culture, bacterial count, identification and typing (phagepyocine and serotyping). Bacterial sensitivity to cefuroxime by using 30 jig Blood analysis for haemoglobin, total and differential white blood cell count, erythrocyte sedimentation rate (Westergren), alkaline phosphatase, serum glutamic oxaloacetic and glutamic pyruvic transaminases, creatinine and blood urea nitrogen. Antibiotic assay. Concentrations of cefuroxime in specimens of serum were determined by microbiological assay. The medium was prepared by dissolving 20.5 g of Oxoid Antibiotic Medium No. 2 and 3 g of sodium citrate in distilled water to give I litre at pH 7.0 and seeding with Bacillus subtilis 1904 E.
Results
Forty cases of urinary tract infections were studied from November 1976-June 1977. A summary of age, sex, weight and height of patients, together with diagnosis, underlying conditions, aetiology, duration of treatment and results of therapy with cefuroxime is given in Table 1 . Clinical results were satisfactory in 36 (90%) of the 40 patients treated with cefuroxime at a dosage of 1500 mg/day, as indicated by relief of symptoms and lack of need for additional antimicrobial therapy. Clinical improvement was observed within the first 2-3 days of treatment. Urine cultures were sterile for 36 (90%) of the 40 patients at the completion of therapy.
However, 3 of these 36 patients developed a new episode of bacteriuria within 6 weeks after cefuroxime therapy. One of these infections was due to relapse and 2 were due to reinfection (Table 2) . Clinical and bacteriological cures were attained in 6 of 7 cases (85.71 %) of complicated chronic pyelonephritis (Table 3 ). All 7 cases of Thirty-three patients (82.5%) were cured, as determined by sterile urine cultures (performed at the end of treatment and 6 weeks later) and by favourable clinical responses. There were 7 failures with the following characteristics.
Superinifection. In cases 8, 21 and 30, cefuroxime treatment successfully eradicated the initial pathogens (Proteus morgonii, Escherichia coli 04 and Escherichia coli 075), but colonization with Pseutdomonas aruginosa occurred.
Reinfectiont wit/h a new pathogen, as occurred in 2 cases (24 and 37). Patient NL, 42 years of age, suffered from chronic urinary tract infection and Proteus mirabilis phagetype 8888 was first isolated in the urine. That organism was eradicated at the end of treatment but in the follow-up a reinfection by a new pathogen (Proteus vulgaris resistant to cefuroxime) developed.
Clinical and bacteriological failures, with persistence of the original pathogen at a level > 105 organisms/mi. Patient MN (case 6) was a 67-yearold female, with chronic pyelonephritis, and past nephrectomy, in whom Escherichia coli 07 was isolated in the urine. After receiving 1500 mg of cefuroxime/day for 7 days, the same strain of Escherichia coli 075 could be detected in the urine.
The minimal inhibitory concentration of the initial pathogen was 4 ,sg of cefuroxime/ml and upon termination of treatment, the MIC was the same value.
Discussion
Sensitivity testing of clinical isolates from our patients supports the finding that cefuroxime has enhanced activity against cephalothin susceptible, Gram negative organisms. Cefuroxime was also active against the Enterobacteriaceaw intrinsically resistant to cephalosporin C like Enterobacter cloaca and indole positive Proteus spp. Thus, 2 strains of Proteus vulgaris, 1 of Proteus morganii, I of Proteuts rettgeri and 1 of Enterobacter cloacta were cephalothin resistant and susceptible to cefuroxime.
Although it is often difficult to determine antimicrobial effectiveness in urinary tract infections in patients with underlying urological problems, bacteriologic efficacy and clinical safety were apparent in our study. The treatment group, 40 patients receiving cefuroxime, were well Relapse (case 23) with elimination of the causative organisms, which appearedagain during follow-up.
As the patients with persistence or relapse should be considered as the only true treatment failures, the overall cure rate was 38 of 40 patients or 95 %. Daily observation of the patients failed to reveal any evidence of clinical side-effects. There were no allergic manifestations and local tolerance to the intramuscularly injected drug was good.
Cefuroxime serum levels, determined on the third day of treatment and 30 min after injection of 500 mg i.m. had a mean value of 22.19 ,ug/ml, a maximum of 26.4 jug/ml and a minimum value of 15.3 ,ug/ml. On the sixth day of therapy the concentration range was 16.2-26.9 ,ug/ml with a mean of 23.35 jug/ml. These high serum levels were coupled with a low degree of protein binding (33%). 
Summary
The clinical and bacteriological efficacy, patient tolerance and toxicity of cefuroxime, a new semisynthetic parenteral cephalosporin with a broad antibacterial spectrum, were evaluated in 40 patients, 16 females and 24 males with ages ranging from 23-74 years. All had urinary tract infections (I05 bacteria/ml) with or without underlying urologic disease, and all were treated with cefuroxime i.m. (500 mg every 8 h) for periods ranging from 7-10 days. Clinical laboratory controls were performed before, during and at the end of treatment and 6 weeks later. The following tests were carried out: urinalysis, WBC, haemoglobin, serum glutamic oxaloacetic and glutamic pyruvic transaminases, bilirubin, alkaline phosphatase, creatinine and blood urea nitrogen.
Identification and typing of microorganisms, disc sensitivity tests, minimal inhibitory concentration and cefuroxime blood levels were also performed.
Results were as follows: clinical and bacteriological cures, 33 cases (82.5 %); failure with superinfection, 3 cases (7.5 %); cure with reinfection, 2 cases (5%); cure with relapse, 1 case (2.5%) and clinical and bacteriological failure, 1 case (2.5 %). No significant hcmatological, renal or hepatic toxicity was observed.
